15 Comments

Such in-depth quality. It's a pleasure to read.

Expand full comment

Thanks, SB! Glad you enjoy it.

Expand full comment

Thank you Devin! As always your article is clear and enjoyable to read.

I need to give credit where credit is due: PMI managed to create a brand from scratch (IQOS). They could have piggybacked on Marlboro. Now IQOS doesn’t have any association to cigarettes, and PMI will be able to use the brand in the US.

Their M&A has been excellent, especially compared to Altria. They managed to buy Swedish Match for a very small premium, and as you point out ZYN’s growth in the US continues to be impressive. Plus they’ll presumably be able to use SM’s sales force and distribution network for IQOS. Their wellness M&A so far hasn’t panned out, but it’s a drop in the bucket compared to SM. So kudos to them!

Expand full comment

The building of IQOS brand equity has been incredible -- perhaps need a piece covering strictly that. Worth noting, the core concept of IQOS was initially developed while PM was still part of Altria. Decades and lots of $$$ spent leading to PM's breakout success.

Expand full comment

They definitely made a great deal on Swedish Match. I got over how furious I was about it as a shareholder and have been rolling the proceeds over to PM on dips.

Expand full comment

While I can sympathize with those wishing Swedish Match remained a standalone company, hard to argue that PMI is not the 'best owner' with its global distribution and immense legal resources. Has a much better shot of a successful global rollout.

Expand full comment

I know!! Same here! PMI paid the smallest premium they had to, knowing no one else could bid more (BTI had too much debt, IMB didn’t have the financial capacity, MO would have run into antitrust issues, etc.) As a SWMA shareholder I was frustrated, but if I had been a PMI shareholder I would have been delighted.

Expand full comment

thanks for the write up!

IRRs of "low-double-digit to mid-teen range" ... is that just dividends + buy backs? Or multiple expansion, too?

Expand full comment

Simply capital returns (majority dividends) and growth reflected at constant current multiple.

Expand full comment

that's pretty good!

Expand full comment

Great analysis! Thanks! What are the odds, in your opinion, that PMI will cut dividend for a period to trim a bit its debt?

Expand full comment

While nothing is off the table *technically*, PMI management has stated the dividend is 'sacrosanct' and will only be going up. Likely no issue managing and reducing debt levels as majority of ILUMA transition lapses and cash from ops grows. Plus, lower total reduction needed as denominators of debt ratios grows.

Expand full comment

Thanks Devin!

Expand full comment

Zyn amazes me, anecdotally a few of the podcasters and influencers I follow have them on show in videos and talk about them unprompted, presumably without compensation. You can just feel the momentum behind that brand in the US

Expand full comment

Very true - I've observed many similar anecdotes. Will be interesting to see how regulation continues to unfold for the category and if/when competitors gain PMTA authorization for new/European versions.

Expand full comment